{
  "response": {
    "text": "The clinical trial NCT00720512, known as the BEBYP trial, investigated the continuation or reintroduction of bevacizumab with second-line chemotherapy for metastatic colorectal cancer. The regimens used in this trial included mFOLFOX-6 or FOLFIRI, depending on the patient's first-line treatment. Bevacizumab was also part of the experimental arm.\n\nFOLFIRI is a chemotherapy regimen that includes Folinic acid, Fluorouracil, and Irinotecan. Irinotecan is described as a topoisomerase I inhibitor.\n\nBased on the information available, Irinotecan is an ingredient in one of the regimens (FOLFIRI) used in clinical trial NCT00720512 and starts with the letter 'I'.\n\nINGREDIENT: IRINOTECAN",
    "citations": []
  }
}